Company intelligence / Profile preview

Otterwise

Newark, Delaware, United Statesgetotterwise.com ↗

Ownership: Private
Development stage: Other

Overview

Otter Biotech develops and manufactures polyclonal and monoclonal antibodies validated for in vitro diagnostic use. Their catalog includes antibodies targeting key biomarkers for cardiovascular, neurological, infectious, and inflammatory conditions. The company also offers custom antibody development services from immunogen design through manufacturing scale-up. No clinical trial results are reported as the focus is on reagents rather than therapeutics.

Therapeutic areas: CardiovascularNeurologyInfectious Diseases
Modalities: Polyclonal antibodyMonoclonal antibodyCustom antibody production
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Otterwise.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otterwise.

Explore the full profile